Xolair 300 MG/2 ML autoinject 2ML
Ended Awarded
- Contract number
- SPE2DB25FZL29
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $10,273
Award facts
- Contract value 100% obligated
- $10,273.38 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, has been awarded a delivery order by the Defense Logistics Agency for $10,273.38 to supply Xolair 300 mg/2 mL auto-injector units. The contract is structured as a firm fixed-price delivery order with an ultimate completion date of October 17, 2025, and carries no set-aside designation. This award is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the Defense Logistics Agency valued at $499,999,999 and valid through November 2026, which authorizes the agency to issue delivery orders for a comprehensive range of pharmaceutical products supporting Department of Defense healthcare facilities worldwide.
Xolair (omalizumab) is a monoclonal antibody medication primarily used for treating moderate to severe allergic asthma and chronic idiopathic urticaria. The delivery order reflects DMS Pharmaceutical Group's established role as a key supplier within the federal pharmaceutical supply chain, providing specialty pharmaceuticals and biologics to military health facilities. The company's contract portfolio demonstrates consistent success in securing pharmaceutical distribution agreements with the Defense Logistics Agency across diverse product categories, including injectable medications, specialty treatments, and medical consumables essential to military healthcare operations.
Quick answers
Who was awarded contract SPE2DB25FZL29?
SPE2DB25FZL29 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on September 25, 2025.
How much is contract SPE2DB25FZL29 worth?
The government has obligated $10,273 on SPE2DB25FZL29.
Is contract SPE2DB25FZL29 an order under another contract?
Yes. SPE2DB25FZL29 is a delivery order under SPE2DB20D9329, an indefinite delivery contract.
Was contract SPE2DB25FZL29 competed?
The extent of competition for SPE2DB25FZL29 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award